COMMUNIQUÉS West-GlobeNewswire

Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
28/03/2024
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the [...]
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
28/03/2024
Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital $50 million financing upfront with up to an additional $99.4 million tied to exercise of [...]
Assure Holdings Closes Sale of Certain Assets to MPOWERHealth
28/03/2024
DENVER, March 28, 2024 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“IONM”) and remote neurology services, today announced that it [...]
Dyadic Announces Change in Board and Management Leadership Roles
28/03/2024
JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of [...]
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
28/03/2024
First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF) Expansion of U.S. [...]
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
28/03/2024
Collaborative Study involving the VA and UCSD achieved statistically significant decrease in PCS and PTSD symptoms versus control group The data supports the Company’s strategy to offer military and civilian physicians [...]
SweetWater Brewing Launches Hammer Red Amber Ale to Support Georgia Aquarium
28/03/2024
The Limited-Release Seasonal Is Part of SweetWater’s On-going Partnership with Georgia Aquarium ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- SweetWater Brewing Company (“SweetWater Brewing” or “SweetWater”), the largest [...]
Psychemedics Corporation Reports 2023 Financial Results
28/03/2024
DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, announced today financial results for the year ended December 31, 2023 [...]
Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference
28/03/2024
Collaborators at the University of Michigan will present new Data on InFoods ® IBS in the DDW Irritable Bowel Syndrome (IBS) Clinical Session IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: [...]
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
28/03/2024
As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with NARCAN ® Nasal Spray and build on its longstanding efforts with [...]
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
28/03/2024
HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of [...]
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
28/03/2024
AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of [...]
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
28/03/2024
On track for topline data from CAN-2409 phase 3 in localized intermediate/high risk prostate cancer, expected in Q4 2024 Results from ongoing, first-in-human, phase 1b clinical trial of CAN-3110, in recurrent high-grade [...]
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
28/03/2024
Live webcast presentation on Wednesday, April 3rd at 1:35 PM ET OCALA, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, MS [...]
Unity Consortium Marks Adolescent Immunization Action Week (AIAW) with activities to help Parents and Adolescents get up to date on Recommended Vaccines
28/03/2024
Unity encourages parents and adolescents to Stay on TASK during AIAW, April 1-5 VENTNOR CITY, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- UNITY® Consortium, a non-profit organization focused on preventive health and [...]
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
28/03/2024
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 [...]
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
28/03/2024
WARREN, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell [...]
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
28/03/2024
CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and [...]
Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL
28/03/2024
Providence, RI, March 28, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. ( NASDAQ: OCEA ), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, today [...]

Pages